5-(氯代磺酰基)-2-糠酸甲酯 | 69816-05-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-(氯代磺酰基)-2-糠酸甲酯
• 中文别名: 5-(氯磺酰基)-2-糠酸甲酯；5-氯磺酰-2-康酸甲酯
• 英文名称: methyl 5-(chlorosulfonyl)furan-2-carboxylate
• 英文别名: methyl 5-(chlorosulfonyl)-2-furoate；methyl 5-chlorosulfonylfuran-2-carboxylate
• CAS: 69816-05-3
• 化学式: C₆H₅ClO₅S
• mdl: MFCD02180740
• 分子量: 224.622
• InChiKey: JYWNJCAFWPZETG-UHFFFAOYSA-N

物化性质

• 沸点：
  118°C 1mm
• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  82
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2932190090
• 危险品运输编号：
  UN 3265

SDS

Name:	Methyl 5-(chlorosulfonyl)-2-furoate 95+% Material Safety Data Sheet
Synonym:
CAS:	69816-05-3

Section 1 - Chemical Product MSDS Name:Methyl 5-(chlorosulfonyl)-2-furoate 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
69816-05-3	Methyl 5-(chlorosulfonyl)-2-furoate	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 69816-05-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 118 deg C @1mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5ClO5S
Molecular Weight: 225

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 69816-05-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 5-(chlorosulfonyl)-2-furoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 69816-05-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 69816-05-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 69816-05-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(氯代磺酰基)-2-糠酸甲酯 在 氨 作用下， 以 乙醚 为溶剂， 生成 Methyl 5-[(butylcarbamoyl)sulfamoyl]furan-2-carboxylate
  参考文献：
  名称：

  N-(5-carboalkoxyfuran-2-sulfonyl)-N′-丁基脲的合成及降血糖活性

  摘要：

  通过呋喃-2-羧酸与氯磺酸磺化获得的5-硫呋喃-2-羧酸(I)转化为其单钾盐，然后用五氯化磷处理以形成二酰氯(II)。从后者得到2-羧基-呋喃磺酰氯(III)和“二酰胺”(2-羧基呋喃-5磺酰胺，XVIIII)的烷基酯。这里制备的Diamid(221-223~与文献[4]中描述的Diamid(211-212~)的熔点不同，后者合成的起始原料为酸I，经呋喃处理制得-2-羧酸与发烟硫酸 [4]. 我们确定在这种情况下 I 的二钠盐作为

  DOI：

  10.1007/bf01150723
• 作为产物：
  描述：

  呋喃-5-磺酸-2-甲酸 在 氢氧化钾 、 五氯化磷 作用下， 反应 0.5h， 生成 5-(氯代磺酰基)-2-糠酸甲酯
  参考文献：
  名称：

  N-(5-carboalkoxyfuran-2-sulfonyl)-N′-丁基脲的合成及降血糖活性

  摘要：

  通过呋喃-2-羧酸与氯磺酸磺化获得的5-硫呋喃-2-羧酸(I)转化为其单钾盐，然后用五氯化磷处理以形成二酰氯(II)。从后者得到2-羧基-呋喃磺酰氯(III)和“二酰胺”(2-羧基呋喃-5磺酰胺，XVIIII)的烷基酯。这里制备的Diamid(221-223~与文献[4]中描述的Diamid(211-212~)的熔点不同，后者合成的起始原料为酸I，经呋喃处理制得-2-羧酸与发烟硫酸 [4]. 我们确定在这种情况下 I 的二钠盐作为

  DOI：

  10.1007/bf01150723

文献信息

• [EN] CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS<br/>[FR] DÉRIVÉS DE CINNOLINE UTILES EN TANT QU'AGONISTES INVERSES DE RÉCEPTEURS CB-1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016115013A1

  公开（公告）日：2016-07-21

  The present invention is directed to cinnoline derivatives of formula (I) pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.

  本发明涉及公式（I）的喹啉衍生物，含有它们的药物组合物以及它们在治疗由CB-1受体介导的疾病和症状中的应用；更具体地，在治疗对CB-1受体的反向激动作用响应的疾病和症状中的应用。更具体地说，本发明的化合物在治疗代谢性疾病中是有用的。
• BORON-CONTAINING SMALL MOLECULES
  申请人：Xia Yi

  公开号：US20100256092A1

  公开（公告）日：2010-10-07

  This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

  这项发明涉及6-取代苯硼酯化合物等物品，以及它们用于治疗细菌感染的用途。
• [EN] NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS CONTENANT UN CYCLE AZOTÉ POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：WEINGARTEN M DAVID

  公开号：WO2012135669A1

  公开（公告）日：2012-10-04

  The invention provides compounds, pharmaceutical compositions and methods of treatment of inflammatory disorders including a compound of Formula I, or its pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative or prodrug wherein R1, R2, R3, R4, X, Y, W, Z and Q are as defined herein.

  这项发明提供了化合物、药物组合物和治疗炎症性疾病的方法，包括式I的化合物，或其药用可接受的盐、酯、药用可接受的衍生物或前药，其中R1、R2、R3、R4、X、Y、W、Z和Q如本文所定义。
• Arylation of <i>gem</i>-difluoroalkenes using a Pd/Cu Co-catalytic system that avoids β-fluoride elimination
  作者：Kedong Yuan、Taisiia Feoktistova、Paul Ha-Yeon Cheong、Ryan A. Altman

  DOI：10.1039/d0sc05192f

  日期：——

  arylation reaction of gem-difluoroalkenes using arylsulfonyl chlorides to deliver α,α-difluorobenzyl products. The reaction proceeds through a β,β-difluoroalkyl–Pd intermediate that typically undergoes unimolecular β-F elimination to deliver monofluorinated alkene products in a net C–F functionalization reaction. However to avoid β-F elimination, we offer the β,β-difluoroalkyl–Pd intermediate an alternate

  Pd II /Cu I共催化gem的芳基化反应-二氟烯烃使用芳基磺酰氯来提供 α,α-二氟苄基产品。该反应通过 β,β-二氟烷基-Pd 中间体进行，该中间体通常经历单分子 β-F 消除，以在净 C-F 官能化反应中提供单氟化烯烃产物。然而，为了避免 β-F 消除，我们为 β,β-二氟烷基-Pd 中间体提供了一种替代低能途径，涉及 β-H 消除，最终以净芳基化/异构化序列提供二氟化产物。总体而言，该反应能够探索不稳定的氟化烷基金属物质的新反应性，同时也为将现成的氟化烯烃转化为更精细的亚结构提供了新的机会。
• [EN] SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] SULFAMOYL-ARYLAMIDES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS DANS LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014033170A1

  公开（公告）日：2014-03-06

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  乙肝病毒复制抑制剂，包括式(I)及其立体异构体、盐、水合物、溶剂化物，其中B、R1、R2和R4的含义如本文所述。本发明还涉及包含这些抑制剂的药物组合物及其用途，单独使用或与其他乙肝病毒抑制剂联合使用，用于乙肝治疗。